Risk Factors Predict PML with Tysabri

Exposure to the JC virus, previous immunosuppressant therapy, and time on natalizumab (Tysbari) appear to predict risk of developing a life-threatening side effect in multiple sclerosis patients, researchers confirmed.

FDA Puts New Limits on Oral MS Drug

WASHINGTON -- Reacting to a death associated with the multiple sclerosis drug fingolimod (Gilenya), the FDA said patients with certain cardiac risk factors should not take the oral agent.

Study Confirms Marijuana Helps in MS

Smoking marijuana cuts spasticity and pain that's resistant to conventional therapy in multiple sclerosis, although with some cognitive effects, a small clinical trial affirmed.

FDA Warns on Controversial MS Therapy

WASHINGTON -- The FDA has issued an alert about risks, including death, associated with treatment of chronic cerebrospinal venous insufficiency (CCSVI), which some believe causes or exacerbates multiple sclerosis.